Which patients with advanced cancer and biliary obstruction benefit from biliary stenting most? An analysis of prognostic factors
Background Patients with advanced cancer may present with obstructive jaundice. Biliary stenting is the treatment of choice. However, which patients benefit most is not well-defined, yet. Our aim was to delineate the clinical factors affecting prognosis. Material and methods Charts of 140 patients w...
Gespeichert in:
| Veröffentlicht in: | Supportive care in cancer 2013-04, Vol.21 (4), p.1131-1135 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1135 |
|---|---|
| container_issue | 4 |
| container_start_page | 1131 |
| container_title | Supportive care in cancer |
| container_volume | 21 |
| creator | Abali, Hüseyin Sezer, Ahmet Oğuzkurt, Levent Gürel, Kamil Özkan, Uğur Beşen, Ali Ayberk Sümbül, Ahmet Taner Köse, Fatih Dişel, Umut Muallaoğlu, Sadık Özyılkan, Özgür |
| description | Background
Patients with advanced cancer may present with obstructive jaundice. Biliary stenting is the treatment of choice. However, which patients benefit most is not well-defined, yet. Our aim was to delineate the clinical factors affecting prognosis.
Material and methods
Charts of 140 patients with advanced cancer who underwent biliary stenting were retrospectively analyzed. Their median age was 63.5 years. Of these patients, 73 (52.1 %) were male, 32 (22.9 %) had ECOG PS 1 and 81 (57.9 %) had PS 2. The most frequent cancer types were cholangiocellular cancer (64, 45.7 %) and pancreatic cancer (36, 25.7 %).
Results
Median overall survival (OS) was 141 (95 % CI, 100.7-185.3) days. Female patients lived longer (161.0 vs. 124.0 days) (
p
= 0.036). Those patients with colorectal cancer lived the longest (667.0 days), followed by cholangiocellular (211.0 days), and gastric cancers (106.0 days) (
p
= 0.004). The distribution of primary diagnosis differed significantly between sexes: cholangiocellular cancer was present in 22 (30.1 %) out of 73 men and 42(62.7 %) out of 67 women (chi-square
p
|
| doi_str_mv | 10.1007/s00520-012-1636-z |
| format | Article |
| fullrecord | <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_1314338382</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A336672510</galeid><sourcerecordid>A336672510</sourcerecordid><originalsourceid>FETCH-LOGICAL-c439t-f0ad247d8a4c923e445a52fe44f185ebdf256a81ec14f185dd5e28a40628c6fd3</originalsourceid><addsrcrecordid>eNp1kUuLFTEQhYMoznX0B7iRgBs3PebZj5VcBl8w4EZxGdJJ5d4M3ck1SY_M7Pznpr3jMIqSRUHqO4eqOgg9p-SMEtK9zoRIRhpCWUNb3jY3D9CGCs6bjvPhIdqQQdBGcClP0JOcLwmhXSfZY3TCOOWMinaDfnzde7PHB108hJLxd1_2WNsrHQxYbNaSsA4Wj37yOl3jOOaSFlN8DHiEAM4X7FKc74BcqpEPOzzHXN7gbahyPV1nn3F0-JDiLtSGN9hpU2LKT9Ejp6cMz27rKfry7u3n8w_Nxaf3H8-3F40RfCiNI9oy0dleCzMwDkJILZmr1dFewmgdk63uKRj668daCazCpGW9aZ3lp-jV0beO8G2BXNTss4Fp0gHikhXl6-l63rOKvvwLvYxLqluslOz4IMh9aqcnUD64WJI2q6nact62HZOUVOrsH1R9FmZv4nrA-v-HgB4FJsWcEzh1SH6ul1WUqDV2dYxd1djVGru6qZoXtwMv4wz2TvE75wqwI5BrK-wg3dvov64_AXV5uK4</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1357394082</pqid></control><display><type>article</type><title>Which patients with advanced cancer and biliary obstruction benefit from biliary stenting most? An analysis of prognostic factors</title><source>MEDLINE</source><source>Springer Nature - Complete Springer Journals</source><creator>Abali, Hüseyin ; Sezer, Ahmet ; Oğuzkurt, Levent ; Gürel, Kamil ; Özkan, Uğur ; Beşen, Ali Ayberk ; Sümbül, Ahmet Taner ; Köse, Fatih ; Dişel, Umut ; Muallaoğlu, Sadık ; Özyılkan, Özgür</creator><creatorcontrib>Abali, Hüseyin ; Sezer, Ahmet ; Oğuzkurt, Levent ; Gürel, Kamil ; Özkan, Uğur ; Beşen, Ali Ayberk ; Sümbül, Ahmet Taner ; Köse, Fatih ; Dişel, Umut ; Muallaoğlu, Sadık ; Özyılkan, Özgür</creatorcontrib><description>Background
Patients with advanced cancer may present with obstructive jaundice. Biliary stenting is the treatment of choice. However, which patients benefit most is not well-defined, yet. Our aim was to delineate the clinical factors affecting prognosis.
Material and methods
Charts of 140 patients with advanced cancer who underwent biliary stenting were retrospectively analyzed. Their median age was 63.5 years. Of these patients, 73 (52.1 %) were male, 32 (22.9 %) had ECOG PS 1 and 81 (57.9 %) had PS 2. The most frequent cancer types were cholangiocellular cancer (64, 45.7 %) and pancreatic cancer (36, 25.7 %).
Results
Median overall survival (OS) was 141 (95 % CI, 100.7-185.3) days. Female patients lived longer (161.0 vs. 124.0 days) (
p
= 0.036). Those patients with colorectal cancer lived the longest (667.0 days), followed by cholangiocellular (211.0 days), and gastric cancers (106.0 days) (
p
= 0.004). The distribution of primary diagnosis differed significantly between sexes: cholangiocellular cancer was present in 22 (30.1 %) out of 73 men and 42(62.7 %) out of 67 women (chi-square
p
< 0.001). There was a trend for longer overall survival if ALT (
p
= 0.08) and AST (
p
= 0.06) were normalized after stent insertion. Of the 137 patients, 63 (45.5 %) did not experience any complication. In 74 patients with complications, there were 39 (28.5 %) episodes of cholangitic infections and 35 (25.5 %) biliary obstructions. In three patients, we could not find data on infections.
Conclusion
Underlying malignancy, hence the natural biology and the therapeutic expectations are probably the most important factors which must be considered during decision-making.</description><identifier>ISSN: 0941-4355</identifier><identifier>EISSN: 1433-7339</identifier><identifier>DOI: 10.1007/s00520-012-1636-z</identifier><identifier>PMID: 23132146</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer-Verlag</publisher><subject>Adult ; Aged ; Aged, 80 and over ; Analysis ; Cancer ; Cancer patients ; Care and treatment ; Chemotherapy ; Colorectal cancer ; Confidence Intervals ; Female ; Gastric cancer ; Humans ; Jaundice, Obstructive - etiology ; Jaundice, Obstructive - surgery ; Male ; Medical Audit ; Medical prognosis ; Medicine ; Medicine & Public Health ; Metastasis ; Middle Aged ; Neoplasms - complications ; Neoplasms - pathology ; Nursing ; Nursing Research ; Oncology ; Original Article ; Outcome Assessment (Health Care) - methods ; Pain Medicine ; Pancreatic cancer ; Patients ; Prognosis ; Rehabilitation Medicine ; Retrospective Studies ; Sexes ; Stent (Surgery) ; Stents ; Survival Analysis</subject><ispartof>Supportive care in cancer, 2013-04, Vol.21 (4), p.1131-1135</ispartof><rights>Springer-Verlag Berlin Heidelberg 2012</rights><rights>COPYRIGHT 2013 Springer</rights><rights>Springer-Verlag Berlin Heidelberg 2013</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c439t-f0ad247d8a4c923e445a52fe44f185ebdf256a81ec14f185dd5e28a40628c6fd3</citedby><cites>FETCH-LOGICAL-c439t-f0ad247d8a4c923e445a52fe44f185ebdf256a81ec14f185dd5e28a40628c6fd3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s00520-012-1636-z$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s00520-012-1636-z$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23132146$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Abali, Hüseyin</creatorcontrib><creatorcontrib>Sezer, Ahmet</creatorcontrib><creatorcontrib>Oğuzkurt, Levent</creatorcontrib><creatorcontrib>Gürel, Kamil</creatorcontrib><creatorcontrib>Özkan, Uğur</creatorcontrib><creatorcontrib>Beşen, Ali Ayberk</creatorcontrib><creatorcontrib>Sümbül, Ahmet Taner</creatorcontrib><creatorcontrib>Köse, Fatih</creatorcontrib><creatorcontrib>Dişel, Umut</creatorcontrib><creatorcontrib>Muallaoğlu, Sadık</creatorcontrib><creatorcontrib>Özyılkan, Özgür</creatorcontrib><title>Which patients with advanced cancer and biliary obstruction benefit from biliary stenting most? An analysis of prognostic factors</title><title>Supportive care in cancer</title><addtitle>Support Care Cancer</addtitle><addtitle>Support Care Cancer</addtitle><description>Background
Patients with advanced cancer may present with obstructive jaundice. Biliary stenting is the treatment of choice. However, which patients benefit most is not well-defined, yet. Our aim was to delineate the clinical factors affecting prognosis.
Material and methods
Charts of 140 patients with advanced cancer who underwent biliary stenting were retrospectively analyzed. Their median age was 63.5 years. Of these patients, 73 (52.1 %) were male, 32 (22.9 %) had ECOG PS 1 and 81 (57.9 %) had PS 2. The most frequent cancer types were cholangiocellular cancer (64, 45.7 %) and pancreatic cancer (36, 25.7 %).
Results
Median overall survival (OS) was 141 (95 % CI, 100.7-185.3) days. Female patients lived longer (161.0 vs. 124.0 days) (
p
= 0.036). Those patients with colorectal cancer lived the longest (667.0 days), followed by cholangiocellular (211.0 days), and gastric cancers (106.0 days) (
p
= 0.004). The distribution of primary diagnosis differed significantly between sexes: cholangiocellular cancer was present in 22 (30.1 %) out of 73 men and 42(62.7 %) out of 67 women (chi-square
p
< 0.001). There was a trend for longer overall survival if ALT (
p
= 0.08) and AST (
p
= 0.06) were normalized after stent insertion. Of the 137 patients, 63 (45.5 %) did not experience any complication. In 74 patients with complications, there were 39 (28.5 %) episodes of cholangitic infections and 35 (25.5 %) biliary obstructions. In three patients, we could not find data on infections.
Conclusion
Underlying malignancy, hence the natural biology and the therapeutic expectations are probably the most important factors which must be considered during decision-making.</description><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Analysis</subject><subject>Cancer</subject><subject>Cancer patients</subject><subject>Care and treatment</subject><subject>Chemotherapy</subject><subject>Colorectal cancer</subject><subject>Confidence Intervals</subject><subject>Female</subject><subject>Gastric cancer</subject><subject>Humans</subject><subject>Jaundice, Obstructive - etiology</subject><subject>Jaundice, Obstructive - surgery</subject><subject>Male</subject><subject>Medical Audit</subject><subject>Medical prognosis</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Metastasis</subject><subject>Middle Aged</subject><subject>Neoplasms - complications</subject><subject>Neoplasms - pathology</subject><subject>Nursing</subject><subject>Nursing Research</subject><subject>Oncology</subject><subject>Original Article</subject><subject>Outcome Assessment (Health Care) - methods</subject><subject>Pain Medicine</subject><subject>Pancreatic cancer</subject><subject>Patients</subject><subject>Prognosis</subject><subject>Rehabilitation Medicine</subject><subject>Retrospective Studies</subject><subject>Sexes</subject><subject>Stent (Surgery)</subject><subject>Stents</subject><subject>Survival Analysis</subject><issn>0941-4355</issn><issn>1433-7339</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNp1kUuLFTEQhYMoznX0B7iRgBs3PebZj5VcBl8w4EZxGdJJ5d4M3ck1SY_M7Pznpr3jMIqSRUHqO4eqOgg9p-SMEtK9zoRIRhpCWUNb3jY3D9CGCs6bjvPhIdqQQdBGcClP0JOcLwmhXSfZY3TCOOWMinaDfnzde7PHB108hJLxd1_2WNsrHQxYbNaSsA4Wj37yOl3jOOaSFlN8DHiEAM4X7FKc74BcqpEPOzzHXN7gbahyPV1nn3F0-JDiLtSGN9hpU2LKT9Ejp6cMz27rKfry7u3n8w_Nxaf3H8-3F40RfCiNI9oy0dleCzMwDkJILZmr1dFewmgdk63uKRj668daCazCpGW9aZ3lp-jV0beO8G2BXNTss4Fp0gHikhXl6-l63rOKvvwLvYxLqluslOz4IMh9aqcnUD64WJI2q6nact62HZOUVOrsH1R9FmZv4nrA-v-HgB4FJsWcEzh1SH6ul1WUqDV2dYxd1djVGru6qZoXtwMv4wz2TvE75wqwI5BrK-wg3dvov64_AXV5uK4</recordid><startdate>20130401</startdate><enddate>20130401</enddate><creator>Abali, Hüseyin</creator><creator>Sezer, Ahmet</creator><creator>Oğuzkurt, Levent</creator><creator>Gürel, Kamil</creator><creator>Özkan, Uğur</creator><creator>Beşen, Ali Ayberk</creator><creator>Sümbül, Ahmet Taner</creator><creator>Köse, Fatih</creator><creator>Dişel, Umut</creator><creator>Muallaoğlu, Sadık</creator><creator>Özyılkan, Özgür</creator><general>Springer-Verlag</general><general>Springer</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>0-V</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88J</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>ALSLI</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HEHIP</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>M2R</scope><scope>M2S</scope><scope>NAPCQ</scope><scope>PHGZM</scope><scope>PHGZT</scope><scope>PJZUB</scope><scope>PKEHL</scope><scope>POGQB</scope><scope>PPXIY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PRQQA</scope><scope>Q9U</scope><scope>7X8</scope></search><sort><creationdate>20130401</creationdate><title>Which patients with advanced cancer and biliary obstruction benefit from biliary stenting most? An analysis of prognostic factors</title><author>Abali, Hüseyin ; Sezer, Ahmet ; Oğuzkurt, Levent ; Gürel, Kamil ; Özkan, Uğur ; Beşen, Ali Ayberk ; Sümbül, Ahmet Taner ; Köse, Fatih ; Dişel, Umut ; Muallaoğlu, Sadık ; Özyılkan, Özgür</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c439t-f0ad247d8a4c923e445a52fe44f185ebdf256a81ec14f185dd5e28a40628c6fd3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Analysis</topic><topic>Cancer</topic><topic>Cancer patients</topic><topic>Care and treatment</topic><topic>Chemotherapy</topic><topic>Colorectal cancer</topic><topic>Confidence Intervals</topic><topic>Female</topic><topic>Gastric cancer</topic><topic>Humans</topic><topic>Jaundice, Obstructive - etiology</topic><topic>Jaundice, Obstructive - surgery</topic><topic>Male</topic><topic>Medical Audit</topic><topic>Medical prognosis</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Metastasis</topic><topic>Middle Aged</topic><topic>Neoplasms - complications</topic><topic>Neoplasms - pathology</topic><topic>Nursing</topic><topic>Nursing Research</topic><topic>Oncology</topic><topic>Original Article</topic><topic>Outcome Assessment (Health Care) - methods</topic><topic>Pain Medicine</topic><topic>Pancreatic cancer</topic><topic>Patients</topic><topic>Prognosis</topic><topic>Rehabilitation Medicine</topic><topic>Retrospective Studies</topic><topic>Sexes</topic><topic>Stent (Surgery)</topic><topic>Stents</topic><topic>Survival Analysis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Abali, Hüseyin</creatorcontrib><creatorcontrib>Sezer, Ahmet</creatorcontrib><creatorcontrib>Oğuzkurt, Levent</creatorcontrib><creatorcontrib>Gürel, Kamil</creatorcontrib><creatorcontrib>Özkan, Uğur</creatorcontrib><creatorcontrib>Beşen, Ali Ayberk</creatorcontrib><creatorcontrib>Sümbül, Ahmet Taner</creatorcontrib><creatorcontrib>Köse, Fatih</creatorcontrib><creatorcontrib>Dişel, Umut</creatorcontrib><creatorcontrib>Muallaoğlu, Sadık</creatorcontrib><creatorcontrib>Özyılkan, Özgür</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Social Sciences Premium Collection</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Social Science Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>Social Science Premium Collection</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Sociology Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Social Science Database</collection><collection>Sociology Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest Central (New)</collection><collection>ProQuest One Academic (New)</collection><collection>ProQuest Health & Medical Research Collection</collection><collection>ProQuest One Academic Middle East (New)</collection><collection>ProQuest Sociology & Social Sciences Collection</collection><collection>ProQuest One Health & Nursing</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest One Social Sciences</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>Supportive care in cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Abali, Hüseyin</au><au>Sezer, Ahmet</au><au>Oğuzkurt, Levent</au><au>Gürel, Kamil</au><au>Özkan, Uğur</au><au>Beşen, Ali Ayberk</au><au>Sümbül, Ahmet Taner</au><au>Köse, Fatih</au><au>Dişel, Umut</au><au>Muallaoğlu, Sadık</au><au>Özyılkan, Özgür</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Which patients with advanced cancer and biliary obstruction benefit from biliary stenting most? An analysis of prognostic factors</atitle><jtitle>Supportive care in cancer</jtitle><stitle>Support Care Cancer</stitle><addtitle>Support Care Cancer</addtitle><date>2013-04-01</date><risdate>2013</risdate><volume>21</volume><issue>4</issue><spage>1131</spage><epage>1135</epage><pages>1131-1135</pages><issn>0941-4355</issn><eissn>1433-7339</eissn><abstract>Background
Patients with advanced cancer may present with obstructive jaundice. Biliary stenting is the treatment of choice. However, which patients benefit most is not well-defined, yet. Our aim was to delineate the clinical factors affecting prognosis.
Material and methods
Charts of 140 patients with advanced cancer who underwent biliary stenting were retrospectively analyzed. Their median age was 63.5 years. Of these patients, 73 (52.1 %) were male, 32 (22.9 %) had ECOG PS 1 and 81 (57.9 %) had PS 2. The most frequent cancer types were cholangiocellular cancer (64, 45.7 %) and pancreatic cancer (36, 25.7 %).
Results
Median overall survival (OS) was 141 (95 % CI, 100.7-185.3) days. Female patients lived longer (161.0 vs. 124.0 days) (
p
= 0.036). Those patients with colorectal cancer lived the longest (667.0 days), followed by cholangiocellular (211.0 days), and gastric cancers (106.0 days) (
p
= 0.004). The distribution of primary diagnosis differed significantly between sexes: cholangiocellular cancer was present in 22 (30.1 %) out of 73 men and 42(62.7 %) out of 67 women (chi-square
p
< 0.001). There was a trend for longer overall survival if ALT (
p
= 0.08) and AST (
p
= 0.06) were normalized after stent insertion. Of the 137 patients, 63 (45.5 %) did not experience any complication. In 74 patients with complications, there were 39 (28.5 %) episodes of cholangitic infections and 35 (25.5 %) biliary obstructions. In three patients, we could not find data on infections.
Conclusion
Underlying malignancy, hence the natural biology and the therapeutic expectations are probably the most important factors which must be considered during decision-making.</abstract><cop>Berlin/Heidelberg</cop><pub>Springer-Verlag</pub><pmid>23132146</pmid><doi>10.1007/s00520-012-1636-z</doi><tpages>5</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0941-4355 |
| ispartof | Supportive care in cancer, 2013-04, Vol.21 (4), p.1131-1135 |
| issn | 0941-4355 1433-7339 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1314338382 |
| source | MEDLINE; Springer Nature - Complete Springer Journals |
| subjects | Adult Aged Aged, 80 and over Analysis Cancer Cancer patients Care and treatment Chemotherapy Colorectal cancer Confidence Intervals Female Gastric cancer Humans Jaundice, Obstructive - etiology Jaundice, Obstructive - surgery Male Medical Audit Medical prognosis Medicine Medicine & Public Health Metastasis Middle Aged Neoplasms - complications Neoplasms - pathology Nursing Nursing Research Oncology Original Article Outcome Assessment (Health Care) - methods Pain Medicine Pancreatic cancer Patients Prognosis Rehabilitation Medicine Retrospective Studies Sexes Stent (Surgery) Stents Survival Analysis |
| title | Which patients with advanced cancer and biliary obstruction benefit from biliary stenting most? An analysis of prognostic factors |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-15T14%3A05%3A46IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Which%20patients%20with%20advanced%20cancer%20and%20biliary%20obstruction%20benefit%20from%20biliary%20stenting%20most?%20An%20analysis%20of%20prognostic%20factors&rft.jtitle=Supportive%20care%20in%20cancer&rft.au=Abali,%20H%C3%BCseyin&rft.date=2013-04-01&rft.volume=21&rft.issue=4&rft.spage=1131&rft.epage=1135&rft.pages=1131-1135&rft.issn=0941-4355&rft.eissn=1433-7339&rft_id=info:doi/10.1007/s00520-012-1636-z&rft_dat=%3Cgale_proqu%3EA336672510%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1357394082&rft_id=info:pmid/23132146&rft_galeid=A336672510&rfr_iscdi=true |